9.05
9.05 (0%)
As of Feb 14, 2025
Biocryst Pharmaceuticals Inc [BCRX]
Source:
Company Overview
Biocryst Pharmaceuticals Inc is a global biotechnology company with a deep commitment to improving the lives of people living with hereditary angioedema (“HAE”) and other rare diseases. We leverage our expertise in structure-guided drug design with the goal of developing first-in-class or best-in-class oral small-molecule and injectable protein therapeutics to target difficult-to-treat rare diseases.
| Country | United States |
| Headquarters | durham, north carolina |
| Phone Number | (919) 859-1302 |
| Industry | manufacturing |
| CEO | Jon P. Stonehouse |
| Website | www.biocryst.com |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | $450.7 |
| Operating Profit | $-2.5 |
| Net Income | $-88.9 |
| Net Cash | $-6.1 |
Profit Ratios
| Gross Margin | $438.4 |
| Operating Margin | -0.6 |
| Profit as % of Revenues | -493.3% |
| Profit as % of Assets | -17.7% |
| Profit as % of Stockholder Equity | 18.7% |
Management Effectiveness
| Return on Equity | 18.7% |
| Return on Assets | -18.1% |
| Turnover Ratio | 89.5% |
| EBITA | $-2.5 |
Balance Sheet and Cash Flow Measures
| Total Assets | $490.4 |
| Total Liabilities | $966.4 |
| Operating Cash Flow | $-52 |
| Investing Cash Flow | $52.6 |
| Financing Cash Flow | $-5.8 |
